Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02407509
Title Phase I Trial of RO5126766 Alone and in Combination With Everolimus (RAF/MEK)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Royal Marsden NHS Foundation Trust

Advanced Solid Tumor

multiple myeloma



Everolimus + RO5126766

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST